Navigation Links
Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance

Support for Medical Use Approval and Insurance Coverage Varies Greatly for Different Medical Treatments


ROCHESTER, N.Y. - April 30, 2007-- Most U.S. adults support approving the use of medical treatments and procedures that can impact people's quality of life, including birth control treatments, in-vitro fertilization, drugs to treat erectile dysfunction and improve memory and to help with weight loss. Large majorities also believe these types of treatments should be covered by health insurance. Support for approval and coverage diminishes for treatments that primarily impact people's personal appearance, such as drugs to reduce the appearance of wrinkles, plastic surgery to help people look younger and growth hormones to help children grow taller.


These are some of the results of an online survey of 2,402 U.S. adults, ages 18 and older, conducted by Harris Interactive(r) between March 20 and 22, 2007 for The Wall Street Journal Online's Health Industry Edition (www.wsj.com/health).


Approval for Medical Use

Strong majorities support the approval of medical treatments such as birth-control pills and other birth-control procedures (88%), drugs that improve memory (77%) and in-vitro fertilization (76%) if they are generally safe and effective. Men are more likely than women to believe that treatments impacting people's personal appearance, such as drugs that help with weight loss (68% vs. 67%, respectively) or plastic surgery (52% vs. 46%) should be approved.


What Should Insurance Cover?

Eight in ten (81%) adults believe that birth-control pills and other birth-control procedures should be covered by health insurance, at least in some part and two-thirds (63%) support coverage for in-vitro fertilization. Women are more likely than men to feel that birth-control treatments (88% vs. 72%) and
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
6. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
7. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
Post Your Comments:
(Date:4/21/2015)... MONROVIA, Calif. , April 21, 2015 ... developer, manufacturer and marketer of implantable lenses and delivery ... of Directors has appointed J. Steven Roush , ... total number of members on STAAR,s Board to seven.Mr. ... reporting agencies expertise, largely gained over a 39 year ...
(Date:4/21/2015)... and CAMBRIDGE, Mass. ... ( Tokyo : 4503) and Potenza ... of immuno-oncology programs, today announced an exclusive research ... is to advance a portfolio consisting of programs ... pathways, co-stimulatory signals and regulatory T cells. The ...
(Date:4/21/2015)... TOKYO , April 21, 2015 /PRNewswire/ ... conferences, has just announced Medtech Partnering Forum 2015 ... technology industry. The event, held May 28–29 in ... international medtech partnering conference in Japan ... new developments in the rapidly changing medical technology industry ...
Breaking Medicine Technology:J. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors 2J. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors 3Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics 2Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics 3Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 2Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 3Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 4
... Feb. 9, 2011 GeoVax Labs, Inc. (OTC Bulletin ... develops and tests innovative HIV/AIDS vaccines, announced today the ... Alabama Vaccine Research Clinic (AVRC) of the University of ... therapeutic vaccine trial. Although the GeoVax vaccines are currently ...
... The Covaris® LE220™ high performance ultra-sonicator has received ... at the LabAutomation 2011 conference in Palm Springs ... laboratory automation conference and exhibition, bringing science, technology, and ... LabAutomation are evaluated by a team of industry experts. ...
Cached Medicine Technology:GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 2GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 3Covaris Receives the Society for Laboratory Automation and Screening (SLAS) New Product Award at LabAutomation 2011 2
(Date:4/21/2015)... Displays & Exhibits, Inc. a division ... show exhibit building industry, announced a management change of ... Absolute Exhibits in Tustin, California.“It is very important to ... the variation in quality as offered by overseas trade ... Adduru. Mr. Adduru is the new manager of Displays ...
(Date:4/21/2015)... 2015 On April 2, 2015, Elle ... Achieve Kylie Jenner Lips With Disastrous Results,” ... themselves while attempting an at-home lip augmentation ... that creating an airlock around one’s mouth for several ... and achieve Kylie Jenner’s now famous pout. (see: goo.gl/dFQW2L) ...
(Date:4/21/2015)... 21, 2015 Top medical tourism firm, ... for their ongoing commitment to providing superior patient experiences. ... provide patients with the best possible experience for a ... and body. , Executives at Ojas Aesthetic Clinic persistently ... of — nothing about you, without you — through ...
(Date:4/21/2015)... 2015 AvePoint, the established ... today announced a new enhancement to DocAve Policy ... Office 365 Management Activity API. This integration creates a ... and take action on all events that take place ... 365 Management Activity API provides customers with greater transparency ...
(Date:4/21/2015)... 2015 Lyft has announced the ... otolaryngologists, bringing the most advanced speech-recognition technology to ... Otolaryngologists can now experience the full benefits of ... in the industry, Lyft, which offers value-added support ... , “Lyft is very excited to be able ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2
... of two proteins in mammalian embryos prevents the development ... at the Medical College of Wisconsin, Milwaukee, has found. ... issue of Developmental Biology, was led by Stephen Duncan, ... the Medical College. , This is the first study ...
... second monoclonal antibody drug to chemotherapy looks promising for ... Clinic researchers working with the North Central Cancer Treatment ... analysis were released May 15 as part of the ... Oncology. , Researchers found that 95 percent of ...
... Shandong, China, May 16 /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. ... a leading manufacturer and distributor,of high-quality, pharmaceutical grade ... the three months ended March 31, 2008., ... -- Sales increased 64.8% to $20.7 million ...
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that ... presentation at two,upcoming investor conferences., Mr. Myers will ... in London at 9:30 a.m. BST (4:30 a.m. EDT) ... 2008 Mr. Myers will present at the FBR Capital,Markets ...
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... nutraceutical industry engaged in the,development, manufacture and distribution ... products in the People,s Republic,of China ("PRC"), today ... March 31, 2008., First Quarter 2008 ...
... anti-inflammatory medication also known by the trade name Celebrex, ... proliferation measurement of precancerous lesions in the lung, according ... D. Anderson Cancer Center. This finding demonstrates the significance ... at higher risk of developing the disease. , The ...
Cached Medicine News:Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2Health News:Adding epratuzumab to standard therapy 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 12Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3
Used to introduce large devices for vascular intervention....
Used to introduce large devices for vascular intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Medicine Products: